Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

NCT05970666 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Adebrelimab
Hepatocellular Carcinoma
Transformation
Bevacizumab
TACE

Interventions

DRUG: TACE with adebrelimab and bevacizumab

Sponsor

The First Affiliated Hospital of Xiamen University

Collaborators

[object Object]